Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study
Launched by FRED HUTCHINSON CANCER CENTER · Feb 3, 2020
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
OUTLINE:
Participants complete questionnaire over 20 minutes at baseline, then undergo collection of saliva sample for genetic testing. Participants identified to have an inherited mutation in a deoxyribonucleic acid (DNA) repair gene undergo genetic counseling. Participants whose genetic testing does not indicate an inherited mutation in a DNA repair gene receive a letter thanking them for their participation and emphasizing the importance of ongoing communication with their physician and family members about cancer risk.
Participants will be sent newsletters every year to encourage stud...
Gender
MALE
Eligibility criteria
- • Inclusion Criteria: Case Ascertainment
- • Signed informed consent form providing agreement for germline genetic testing, use and release of health and research information
- • Male aged 35 to 89 years
- • Diagnosis of prostate cancer
- • Resident of Washington state
- • Willing to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history
- • Willing and able to provide a saliva sample
- • United States (U.S.) mailing address
- • Inclusion Criteria: Family Recruitment
- • Signed informed consent form providing agreement for germline genetic testing, use and release of health and research information
- • Males aged 35 to 89 years
- • Willingness to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history
- • Willingness and ability to provide a saliva sample
- • U.S. mailing address
- • Exclusion Criteria: Case Ascertainment
- • Unable to provide informed consent, e.g. decisional impairment
- • Prior bone marrow transplant
- • Currently under treatment for a hematologic malignancy
- • Study team members
- • Exclusion Criteria: Family Recruitment
- • Unable to provide informed consent, e.g. decisional impairment
- • Prior bone marrow transplant
- • Currently under treatment for a hematologic malignancy
- • Study team members
About Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center is a leading nonprofit research institution dedicated to the pursuit of innovative cancer treatments and prevention strategies. Established in Seattle, Washington, the center is renowned for its pioneering work in hematopoietic cell transplantation and its commitment to advancing cancer research through collaborative clinical trials. By integrating cutting-edge science with compassionate patient care, Fred Hutchinson Cancer Center aims to improve outcomes for patients while fostering a multidisciplinary approach to tackling complex cancer challenges. With a strong emphasis on translating research findings into clinical applications, the center is at the forefront of developing novel therapies that offer hope to patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Burcu Darst
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Heather H Cheng
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Daniel W Lin
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Colin C Pritchard
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials